Grace Therapeutics, Inc. (GRCE) vs Harvard Bioscience, Inc. (HBIO)
A side-by-side comparison of Grace Therapeutics, Inc. and Harvard Bioscience, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GRCE
Grace Therapeutics, Inc.
$2.12HealthcareDelayed quote: Oct 6, 2026, 12:06 PM EDT
HBIO
Harvard Bioscience, Inc.
$8.68HealthcareDelayed quote: Oct 6, 2026, 12:09 PM EDT
Total return — GRCE vs HBIO
growth of $100 · dividends reinvested · last 2yGRCE -31.6% (-17.3%/yr)HBIO -68.0% (-43.5%/yr)GRCE compounded faster over this window
GRCE HBIO
GRCE vs HBIO: by the numbers
- •HBIO is the larger company ($39M vs $35M market cap).
- •Both run net losses; GRCE's is the smaller (0.00% vs -11.86% net margin).
Metrics side by side
Valuation
| Metric | GRCE | HBIO |
|---|---|---|
| P/S ratio | N/A | 0.45 |
| P/B ratio | 0.72 | 5.28 |
| EV / EBITDA | N/A | 10.61 |
Profitability
| Metric | GRCE | HBIO |
|---|---|---|
| Gross margin | 0.00% | 58.16% |
| Operating margin | 0.00% | 1.17% |
| Net margin | 0.00% | -11.86% |
| ROE | -44.50% | -140.36% |
| ROIC | -52.61% | 1.99% |
Growth (annualized)
| Metric | GRCE | HBIO |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -4.62% |
| Total return CAGR (5Y) | N/A | -34.33% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.